Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ARCT | Arcturus Therapeutics | $10 | -$13.17 | -0.57% | 3.3M | $628.9M | $8.04$24.17 |
| ATOM | Atomera | $2.91 | -$1.34 | -0.32% | 1.1M | $133.8M | $2.48$17.55 |
| OWLS | Obook | $17.35 | -$2.16 | -0.11% | 45.4K | $1.7B | $10$90 |
| ATMV | AlphaVest Acquisition Corp | $9.96 | -$3.54 | -0.26% | 66.2K | $52.0M | $8$42 |
| OKLL | Tidal Trust II - Defiance Daily Target 2x Long Oklo ETF | $72.74 | -$13.6 | -0.16% | 493.5K | - | $16.09$169.96 |
| GLGG | Themes ETF Trust - Leverage Shares 2x Long Glxy Daily ETF | $33 | -$7.78 | -0.19% | 16.5K | - | $12.38$45.8 |
| VELO | Velo3D, Inc. | $5.73 | -$1.27 | -18.14% | - | - | - |
| AGH | Aureus Greenway | $6.42 | -$0.4 | -0.06% | 16.2K | $99.5M | $0.52$8 |
| NERV | Minerva Neurosciences | $4.86 | -$1.55 | -0.24% | 1.2M | $44.8M | $1.15$12.46 |
| GNPX | Genprex | $9.9 | -$1.6 | -0.14% | 60.3K | $493.4M | $7$157.5 |
Related Articles
Featured Article
Is Richtech Robotics Stock a Buy?
George Budwell|Oct 11, 2025
This robotics upstart has surged 143% year to date, but early-stage revenue and a high price tag raise questions about the artificial intelligence (AI) automation story.
Could Arcturus Therapeutics Be the Next Moderna?
Alex Carchidi|Mar 1, 2022
It's not likely, but it could still end up being a good investment.
Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
Adria Cimino|Oct 15, 2021
The company disappointed last year, but things may be turning around.
Which Late-to-the-Party COVID Vaccine Stocks Could Still Be Winners?
Keith Speights and Brian Orelli, PhD|Mar 14, 2021
There's at least one biotech that appears to be a potential contender.
Is Arcturus Therapeutics a Buy?
Alex Carchidi|Jan 12, 2021
Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.
Did You Miss Out on the Chance for Big Gains from Arcturus Stock?
Adria Cimino|Jan 6, 2021
The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.
Why Is Everyone Talking About Arcturus Therapeutics Stock?
Zhiyuan Sun|Jan 5, 2021
This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.
Markets Ease Lower as Arcturus, Blink Charging Plunge
Dan Caplinger|Dec 29, 2020
Two top performers fell back to earth on Tuesday.
Arcturus Reports Results From Early-Stage Testing of Its Coronavirus Vaccine
Eric Volkman|Dec 29, 2020
Investors obviously considered these to be underwhelming, however.
3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now
Keith Speights|Dec 20, 2020
Nothing compares to these companies.
